Loss of one copy of the DNA ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage. The team identified underlying molecular mechanisms of platinum resistance that they neutralized with combinations…
Source: Medical Xpress
